Effect of Subcutaneous Anti-CD20 Antibody-Mediated B Cell Depletion on Susceptibility to Pneumocystis Infection in Mice

mSphere (Jun 2021)

Affiliations

Guixiang Dai: Center for Translational Research in Infection and Inflammation, Tulane University School of Medicine, New Orleans, Louisiana, USA
Kristin Noell: Center for Translational Research in Infection and Inflammation, Tulane University School of Medicine, New Orleans, Louisiana, USA
Gisbert Weckbecker: Novartis, Basel, Switzerland
Jay K. Kolls: ORCiD; Center for Translational Research in Infection and Inflammation, Tulane University School of Medicine, New Orleans, Louisiana, USA

Abstract

Anti-CD20 antibody therapy is used for both cancer and autoimmune disease but has been shown to be associated with PneumocystisPneumocystis